Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Combination Tirzepatide and Levonorgestrel Intrauterine Device Therapy for Endometrial Intraepithelial Neoplasia (EIN) and Grade 1 Endometrioid Endometrial Carcinoma: A Pilot Window-of-Opportunity Study

NCT07812636 is registered in ClinicalTrials.gov with Milton S. Hershey Medical Center as lead sponsor.

NCT NCT07812636
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT07812636 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Combination Tirzepatide and Levonorgestrel Intrauterine Device Therapy for Endometrial Intraepithelial Neoplasia (EIN) and Grade 1 Endometrioid Endometrial Carcinoma: A Pilot Window-of-Opportunity Study
Lead sponsor
Milton S. Hershey Medical Center
Phase
Phase 1
Overall status
Not yet recruiting
Start date
November 1, 2026
Completion date
August 1, 2028
Enrollment
15 (estimated)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

endometrial intraepithelial neoplasia, grade 1 endometrial endometrioid carcinoma, metabolic comorbidities